In addition, loss-of-function mutations in triggering receptor expressed on myeloid cells 2, which is upregulated by CD33-related SIGLEC receptors, are linked to a nonresponsive microglial phenotype and an increased risk of Alzheimer’s disease [120]. This evidence concerns the gene CD33 and Alzheimer disease.